http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110156887-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-705 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-08 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08 |
| filingDate | 2018-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2023-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2023-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110156887-B |
| titleOfInvention | Human VASN protein antigen epitope, antigen mimic epitope and use thereof |
| abstract | The invention belongs to the fields of molecular biology, immunology and cell biology, and relates to a human VASN protein epitope, a preparation method and application thereof. Through phage screening technology, two epitope peptides VP1 and VP2 were obtained, which had high homology with the 430‑441 amino acid sequence of VASN protein. Furthermore, through ELISA, competition ELISA, Transwell, CCK-8 and other tests, it was determined that the epitope peptides VP1 and VP2 can antagonize the function of VASN antibody in inhibiting the migration and proliferation of liver cancer cells. Therefore, the VASN (position 430-441) antigenic epitope and its mimetic epitope have good application prospects in the research and development of tumor antibody drugs and tumor vaccines. |
| priorityDate | 2018-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 148.